BruceAJohnsonMD

PubMed

• 4 citations
  Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.
  Ghady Haidar, Jana L Jacobs, Kailey Hughes Kramer, Asma Naqvi, Amy Heaps, Urvi Parikh, Kevin D McCormick, Michele D Sobolewski, Mounzer Agha, Tatiana Bogdanovich, Vasi...> ;Clinical Infectious Diseases. 2023 Sep 11
• 9 citations
  CD4T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor-α/Tumor Necrosis Factor Receptor 1-Dependent.
  Iulia Popescu, Mark E Snyder, Carlo J Iasella, Stefanie J Hannan, Ritchie Koshy, Robin Burke, Antu Das, Mark J Brown, Emily J Lyons, Sophia C Lieber, Xiaoping Chen, Jo...> ;American Journal of Respiratory and Critical Care Medicine. 2022 Jun 15
• 34 citations
  Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors.
  Carlo J. Iasella, Ryan J. Winstead, Cody A. Moore, B.A. Johnson, Ayelet T. Feinberg, Matthew R. Morrell, J.W. Awori Hayanga, Elizabeth A. Lendermon, Adriana Zeevi, Joh...> ;Transplantation. 2018 Jan 1
• 19 citations
  Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation
  Christopher R. Ensor, Lindsey C. Rihtarchik, Matthew R. Morrell, J.W. Awori Hayanga, Alicia B. Lichvar, Joseph M. Pilewski, Stephen R. Wisniewski, B.A. Johnson, Jonath...> ;Clinical Transplantation. 2017 Apr 1
• First successful lung transplantation for sickle cell disease with severe pulmonary arterial hypertension and pulmonary veno-occlusive disease.
  George, M. P.,Novelli, E. M.,Shigemura, N.,Simon, M. A.,Feingold, B.,Krishnamurti, L.,Morrell, M. R.,Gries, C. G.,Haider, S.,Johnson, B. A.,Crespo, M. M.,Bhama, J. K.,...> ;Pulm Circ. 2014 Jul 10
• Lung Deposition and Pharmacokinetics of Nebulized Cyclosporine in Lung Transplant Patients.
  Corcoran, T. E.,Niven, R.,Verret, W.,Dilly, S.,Johnson, B. A.> ;J Aerosol Med Pulm Drug Deliv. 2013 May 13
• Early major neurologic complications after lung transplantation: incidence, risk factors, and outcome.
  Shigemura, N.,Sclabassi, R. J.,Bhama, J. K.,Gries, C. J.,Crespo, M. M.,Johnson, B.,Pilewski, J. M.,Bermudez, C. A.> ;Transplantation. 2013 Mar 27
• Donor smoking history and age in lung transplantation: a revisit.
  Shigemura, N.,Toyoda, Y.,Bhama, J. K.,Gries, C. J.,Crespo, M.,Johnson, B.,Zaldonis, D.,Pilewski, J. M.,Bermudez, C. A.> ;Transplantation. 2013 Feb 15
• Ligand and Receptor Dynamics Contribute to the Mechanism of Graded PPAR? Agonism.
  Hughes, T.S., Chalmers, M.J., Novick, S., Kuruvilla, D.S., Chang, M.R., Kamenecka, T.M., Rance, M., Johnson, B.A., Burris, T.P., Griffin, P.R., Kojetin, D.J.> ;Structure. 2012 Jan 11
• Changing practice paradigms: negotiating your future.
  Satiani, B.B., Motew, S.J., Darling, R.C., Jain, K.M., Wixon, C.L., Johnson, B.A., Weiss, V.J., Gable, D.R.> ;J Vasc Surg. 2012 Apr
• Accountable care organizations and beyond. Position your practice for a quality-based delivery system.
  Johnson, B.A.> ;MGMA Connex. 2010 Apr
• Managing your practice's relationships with legal counsel.
  Johnson, B.A.> ;MGMA Connex. 2008 Aug
• Evaluation of the electronic version of the questionnaire for lung transplant patients.
  Dabbs, A.V., Johnson, B.A., Wardzinski, W.T., Iacono, A.T., Studer, S.M.> ;Prog Transplant. 2007 Mar
• Use of endobronchial valves for native lung hyperinflation associated with respiratory failure in a single-lung transplant recipient for emphysema.
  Crespo, M.M., Johnson, B.A., McCurry, K.R., Landreneau, R.J., Sciurba, F.C.> ;Chest. 2007 Jan
• Tell me true. What is a true group practice?
  Johnson, B.A.> ;MGMA Connex. 2007 Jan
• A randomized trial of inhaled cyclosporine in lung-transplant recipients.
  Iacono, A.T., Johnson, B.A., Grgurich, W.F., Youssef, J.G., Corcoran, T.E., Seiler, D.A., Dauber, J.H., Smaldone, G.C., Zeevi, A., Yousem, S.A., Fung, J.J., Burckart, ...> ;N Engl J Med. 2006 Jan 12
• Reading the tea leaves. Making sense of new legal guidance on ancillary services.
  Johnson, B.A.> ;MGMA Connex. 2005 Jul
• Stark II, phase II. Positive changes and lingering uncertainties.
  Johnson, B.A.> ;MGMA Connex. 2004 Jul
• Stark II, phase II. What it means for physician compensation.
  Johnson, B.A.> ;MGMA Connex. 2004-05-01
• Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity.
  Mortishire-Smith, R.J., Skiles, G.L., Lawrence, J.W., Spence, S., Nicholls, A.W., Johnson, B.A., Nicholson, J.K.> ;Chem Res Toxicol. 2004 Feb
• Using NMRView to visualize and analyze the NMR spectra of macromolecules.
  Johnson, B.A.> ;Methods Mol Biol. 2004
• Statin use is associated with improved function and survival of lung allografts.
  Johnson, B.A., Iacono, A.T., Zeevi, A., McCurry, K.R., Duncan, S.R.> ;Am J Respir Crit Care Med. 2003 May 1
• Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator.
  Berger, J.P., Petro, A.E., Macnaul, K.L., Kelly, L.J., Zhang, B.B., Richards, K., Elbrecht, A., Johnson, B.A., Zhou, G., Doebber, T.W., Biswas, C., Parikh, M., Sharma,...> ;Mol Endocrinol. 2003 Apr
• Clean dealing. Legal considerations for buy/sell agreements.
  Johnson, B.A.> ;MGMA Connex. 2002-11-01
• Join now to see all